3.0.0 2592 2023-01-12T17:53:04Z 2023-01-12T17:53:04Z House H HR 2007-06-06 110 hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2007-06-06T20:09:49Z Referred to 2007-06-06T14:03:30Z 2007-06-06 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2007-06-06 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2007-06-06 Introduced in House IntroReferral Intro-H 9 Library of Congress 2007-06-06 Introduced in House IntroReferral 1000 9 Library of Congress G000554 Rep. Giffords, Gabrielle [D-AZ-8] Gabrielle Giffords D AZ 8 N B001243 Rep. Blackburn, Marsha [R-TN-7] Marsha Blackburn R TN 7 2007-06-06 True H000067 Rep. Hall, Ralph M. [R-TX-4] RALPH HALL R TX M. 4 2007-06-06 True E000179 Rep. Engel, Eliot L. [D-NY-17] ELIOT ENGEL D NY L. 17 2007-06-14 False V000128 Rep. Van Hollen, Chris [D-MD-8] Chris Van Hollen D MD 8 2007-07-11 False Health Administrative remedies Colleges Commerce Conflict of interests Congressional reporting requirements Department of Health and Human Services Drug industry Drugs Education Government Operations and Politics Higher education Law Medical innovations Medical research Medical supplies Medical technology Product development Product safety Public-private partnerships Research and development Science, Technology, Communications Tax-exempt organizations Health

00 2007-06-06 Introduced in House 2007-08-28T21:11:42Z Safe and Effective Drug Development Act of 2007 - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to enter into Critical Path Public-Private Partnerships with eligible entities to implement the Critical Path Initiative of the Food and Drug Administration (FDA) by developing research, education, and outreach projects to foster medical product innovation, accelerate medical product development, and enhance medical product safety. Prohibits such an entity from accepting any funding for the technical programs of a Critical Path Public-Private Partnership from any individual or organization that manufactures, distributes, or sells any FDA-regulated product. Establishes an exception for accepting funds from a consortium of companies whose products are FDA-regulated if the Secretary determines that such acceptance would not result in any conflict of interest and issues a waiver.

]]>

Display Title Official Title as Introduced Introduced in House IH Short Titles as Introduced Introduced in House 2007-06-06T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-110hr2592ih/xml/BILLS-110hr2592ih.xml 2007-06-06 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.